Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other key documents. Vertex is a global biotechnology company with approved medicines in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and a broad clinical pipeline in kidney disease, neuropathic pain, type 1 diabetes and myotonic dystrophy type 1. Its SEC filings give investors and analysts detailed insight into financial performance, risk factors and material events affecting the business.
Recent Form 8-K filings from Vertex have reported quarterly financial results and related guidance under Item 2.02, Results of Operations and Financial Condition. These filings typically reference accompanying press releases that summarize revenue trends, research and development spending and updates across the company’s portfolio, including CFTR modulators such as ALYFTREK and TRIKAFTA, CASGEVY gene-edited cell therapy and JOURNAVX for acute pain. Other 8-K items may address changes in key executives or other corporate developments when they occur.
On Stock Titan, Vertex filings are updated in near real time as they appear on the SEC’s EDGAR system. AI-powered summaries help explain the main points of lengthy documents, so users can quickly understand how new information may relate to VRTX stock without reading every page. For example, AI summaries can highlight key themes in earnings-related 8-Ks, note significant changes in guidance or spending, and point out disclosures related to the progress of pivotal trials or regulatory submissions.
In addition to 8-Ks, users can review Vertex’s annual and quarterly reports when available, as well as any proxy materials and registration statements that may be filed. AI analysis tools on Stock Titan can surface trends across multiple filings, making it easier to track how Vertex’s financial profile and pipeline narrative evolve over time. This page is a useful starting point for anyone researching VRTX from a regulatory and disclosure perspective, complementing price charts, news and other fundamental data.
Vertex Pharmaceuticals director Sangeeta N. Bhatia reported an open-market sale of 266 shares of common stock at $500 per share. After this transaction, she directly owns 4,299 shares. The sale was made under a company-approved Rule 10b5-1 trading plan entered into on 05/27/2025.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported a tax-related share disposition. On February 13, 2026, he disposed of 1,903 shares of Vertex common stock at $487.76 per share as a tax-withholding disposition and now directly holds 20,143 shares of common stock.
Vertex Pharmaceuticals senior executive reports tax-related share disposition
Vertex Pharmaceuticals' SVP & Chief Accounting Officer Kristen Ambrose reported a Form 4 transaction involving a tax-withholding disposition of 1,393 shares of common stock at $487.76 per share on February 13, 2026. This type of transaction reflects shares withheld to cover tax obligations, rather than an open-market sale. After this transaction, Ambrose directly owns 8,734 shares of Vertex common stock.
Ourania Tatsis reported multiple secondary sales of common stock in filings relating to VRTX. The reported transactions list sales of 4,500 shares on 12/03/2025, 4,500 shares on 01/07/2026, 466 shares on 02/11/2026, 1,500 shares on 02/13/2026, and 609 shares on 02/17/2026. The excerpt also shows 368 shares associated with restricted stock vesting from the issuer on 02/17/2026.
Jonathan P. Biller reported sales of Common stock under Rule 144. The filing lists sales of 12/03/2025 ($155,803 for 347 shares), 02/11/2026 ($886,327.75 for 1,925 shares), 02/13/2026 ($493,012 for 988 shares) and 02/17/2026 ($1,211,902.96 for 2,476 shares).
The form also shows a Restricted Stock Vesting entry dated 02/17/2026 with a numeric reference of 1,244, listed under "Securities To Be Sold" with the method described as Compensation.
Vertex Pharmaceuticals reported insider transactions and a restricted‑stock vesting event. The filing lists 1,182 common shares under "Securities To Be Sold" tied to Restricted Stock Vesting on 02/17/2026 as "Issuer" compensation. The filing also records sales by Mark E. Bunnage: 23 shares on 12/29/2025 (10,649.00), 2,021 shares on 02/11/2026 (930,529.03), and 2,437 shares on 02/17/2026 (1,192,814.02).
Vertex Pharmaceuticals filed a Form 144 reporting proposed and recent transactions in its common stock. The filing lists 817 shares to be sold on 02/17/2026 tied to restricted stock vesting, and prior sales by E Morrey Atkinson of 1,751 shares on 02/11/2026 and 2,031 shares on 02/17/2026.
Vertex Pharmaceuticals (VRTX) insider Mark Bunnage filed a notice to sell 2,437 shares of Vertex common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $1,192,814.02, with an approximate sale date of February 17, 2026.
The shares to be sold were acquired on February 13, 2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, Bunnage sold 2,021 Vertex common shares on February 11, 2026 for gross proceeds of $930,529.03 and 23 shares on December 29, 2025 for $10,649.00.
An affiliate of VRTX, identified as Ourania Tatsis, has filed a notice to sell 609 shares of common stock through Fidelity Brokerage Services on NASDAQ around 02/17/2026. These shares were acquired on 02/13/2026 via restricted stock vesting as compensation from the issuer.
The filing also lists recent sales over the prior three months. On 12/03/2025 and 01/07/2026, Tatsis sold 4,500 common shares each, with gross proceeds of 2024955.40 and 2137455.00. Additional sales on 02/11/2026 and 02/13/2026 covered 466 and 1,500 shares, with proceeds of 214560.38 and 749992.02.
An affiliated shareholder has filed notice of an intended sale of 2,476 shares of common stock through Fidelity Brokerage Services LLC on or around February 17, 2026 on the NASDAQ. The filing lists an aggregate market value of $1,211,902.96 for these shares, compared with 254,034,190 shares outstanding.
The shares to be sold were acquired on February 13, 2026 through restricted stock vesting from the issuer as compensation. The notice also details prior sales in the last three months by Jonathan P. Biller, including several smaller common‑stock transactions.